CCDC47 Protein, Human (HEK293, His)

The CCDC47 protein is an important component of the multichannel translocon (MPT) complex, which facilitates the insertion of multichannel membrane proteins into lipid bilayers. It blocks the lateral gate of the SEC61 complex, allowing insertion of subsequent transmembrane domains. CCDC47 Protein, Human (HEK293, His) is the recombinant human-derived CCDC47 protein, expressed by HEK293 , with C-His labeled tag. The total length of CCDC47 Protein, Human (HEK293, His) is 135 a.a., with molecular weight of ~22 kDa.

CCDC47 Protein is a crucial component of the multi-pass translocon (MPT) complex, which facilitates the insertion of multi-pass membrane proteins into the lipid bilayer of membranes. Following initial membrane insertion by the SEC61 complex, the MPT complex takes over and blocks the lateral gate of the SEC61 complex, promoting the insertion of subsequent transmembrane regions. Within the MPT complex, the PAT subcomplex, consisting of CCDC47, plays a role in sequestering highly polar regions in the transmembrane domains away from the non-polar membrane environment until they can be properly buried in the fully assembled protein. Additionally, CCDC47 occludes the lateral gate of the SEC61 complex within the PAT subcomplex. CCDC47 is also involved in regulating calcium ion homeostasis in the endoplasmic reticulum (ER) and is essential for proper protein degradation via the ER-associated degradation (ERAD) pathway. Its presence is necessary for maintaining ER organization during embryogenesis. CCDC47 forms the PAT complex along with WDR83OS/Asterix and is part of the larger MPT complex, which includes the GEL complex (RAB5IF/OPTI and TMCO1), the BOS complex (NCLN/Nicalin, NOMO, and TMEM147), and the PAT complex. The MPT complex interacts with the SEC61 complex and also interacts with VCP, HSPA5, DERL1, DERL2, and SELENOS.

Human

HEK293

C-His

Q96A33 (M1-S135)

57003  [NCBI]

Approximately 22 kDa

Greater than 95% as determined by reducing SDS-PAGE

<1 EU/μg, determined by LAL method.